Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Tiziana Life Sciences ( (TLSA) ) has provided an announcement.
Tiziana Life Sciences has announced the dosing of four additional patients in its Intermediate Size Patient Population Expanded Access program for non-active secondary progressive multiple sclerosis (na-SPMS). As of February 18, 2025, fourteen patients in total have been enrolled in the program, with ten showing improvement or stability within six months of treatment. This program is designed for patients who do not qualify for the ongoing Phase 2a study, reflecting Tiziana’s commitment to addressing unmet medical needs in na-SPMS. The company’s efforts in advancing therapies could have significant implications for patients with neuroinflammatory disorders.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies utilizing transformational drug delivery technologies for immunotherapy. The company’s lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody in clinical development, aimed at providing improved safety, efficacy, and tolerability compared to traditional intravenous delivery methods.
YTD Price Performance: 16.47%
Average Trading Volume: 619,597
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $87.64M
For an in-depth examination of TLSA stock, go to TipRanks’ Stock Analysis page.
